Molecular imaging in the development of a novel treatment paradigm for glioblastoma (GBM): An integrated multidisciplinary commentary

Monika A. Jarzabek, Kieron J. Sweeney, Rhys L. Evans, Andreas H. Jacobs, Roger Stupp, Donncha O'Brien, Mitchel S. Berger, Jochen H M Prehn, Annette T. Byrne*

*Corresponding author for this work

Research output: Contribution to journalReview article

12 Scopus citations

Abstract

Current therapeutic strategies against glioblastoma (GBM) have failed to prevent disease progression and recurrence effectively. The part played by molecular imaging (MI) in the development of novel therapies has gained increasing traction in recent years. For the first time, using expertise from an integrated multidisciplinary group of authors, herein we present a comprehensive evaluation of state-of-the-art GBM imaging and explore how advances facilitate the emergence of new treatment options. We propose a novel next-generation treatment paradigm based on the targeting of multiple hallmarks of cancer evolution that will heavily rely on MI.

Original languageEnglish (US)
Pages (from-to)1052-1066
Number of pages15
JournalDrug Discovery Today
Volume18
Issue number21-22
DOIs
StatePublished - Nov 1 2013

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Jarzabek, M. A., Sweeney, K. J., Evans, R. L., Jacobs, A. H., Stupp, R., O'Brien, D., Berger, M. S., Prehn, J. H. M., & Byrne, A. T. (2013). Molecular imaging in the development of a novel treatment paradigm for glioblastoma (GBM): An integrated multidisciplinary commentary. Drug Discovery Today, 18(21-22), 1052-1066. https://doi.org/10.1016/j.drudis.2013.06.004